John Newman
Stock Analyst at Canaccord Genuity
(2.03)
# 2,921
Out of 5,182 analysts
87
Total ratings
40.7%
Success rate
-7.61%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Maintains: Buy | $13 → $7 | $1.96 | +257.14% | 2 | Apr 28, 2026 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $9 | $1.53 | +488.24% | 1 | Apr 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Buy | $50 | $34.04 | +46.89% | 1 | Apr 6, 2026 | |
| TNGX Tango Therapeutics | Initiates: Buy | $30 | $20.98 | +42.99% | 1 | Apr 2, 2026 | |
| MCRB Seres Therapeutics | Maintains: Buy | $22 | $7.61 | +189.09% | 11 | Mar 13, 2026 | |
| CADL Candel Therapeutics | Maintains: Buy | $25 | $6.47 | +286.40% | 3 | Mar 13, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.15 | +551.16% | 4 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $97.54 | +75.31% | 9 | Mar 11, 2026 | |
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.90 | +22.45% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $8.20 | +119.51% | 7 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $850 → $1,057 | $701.42 | +50.69% | 20 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $126 | $99.04 | +27.22% | 1 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $10.80 | +94.44% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.47 | +444.22% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.20 | +593.55% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.87 | +474.65% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $28.16 | +56.25% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.30 | +185.71% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $1.59 | +1,598.11% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.35 | - | 1 | Sep 13, 2017 |
Compass Therapeutics
Apr 28, 2026
Maintains: Buy
Price Target: $13 → $7
Current: $1.96
Upside: +257.14%
Lineage Cell Therapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $9
Current: $1.53
Upside: +488.24%
Tyra Biosciences
Apr 6, 2026
Initiates: Buy
Price Target: $50
Current: $34.04
Upside: +46.89%
Tango Therapeutics
Apr 2, 2026
Initiates: Buy
Price Target: $30
Current: $20.98
Upside: +42.99%
Seres Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $22
Current: $7.61
Upside: +189.09%
Candel Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $25
Current: $6.47
Upside: +286.40%
Allogene Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $14
Current: $2.15
Upside: +551.16%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $171
Current: $97.54
Upside: +75.31%
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.90
Upside: +22.45%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $8.20
Upside: +119.51%
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $701.42
Upside: +50.69%
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $99.04
Upside: +27.22%
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.80
Upside: +94.44%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.47
Upside: +444.22%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.20
Upside: +593.55%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.87
Upside: +474.65%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $28.16
Upside: +56.25%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.30
Upside: +185.71%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $1.59
Upside: +1,598.11%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.35
Upside: -